<DOC>
	<DOCNO>NCT00004048</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . Chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy radioimmunotherapy chemotherapy use kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radioimmunotherapy without doxorubicin plus peripheral stem cell transplantation treat patient thyroid cancer .</brief_summary>
	<brief_title>Radioimmunotherapy With Without Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity high dose yttrium Y 90 monoclonal antibody MN-14 without doxorubicin plus peripheral blood stem cell rescue patient medullary thyroid cancer . II . Correlate organ tumor dosimetry toxicity antitumor responses patient . III . Assess response duration response patient treatment . OUTLINE : This dose escalation study yttrrium Y 90 monoclonal antibody MN-14 ( 90Y-MN-14 ) . Patients stratify prior doxorubicin ( yes v ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SQ ) day -11 -7 undergo leukapheresis day -8 -6 . If adequate number CD34+ cell harvest , bone marrow also collect . Patients receive pretherapy target consist indium In 111 monoclonal antibody MN-14 ( In111-MN-14 ) day 0 . At least 1 confirmed tumor site must target . Patients receive 90Y-MN-14 IV 30-45 minute day 7 . Some patient also receive doxorubicin IV day 8 . PBSC bone marrow reinfused approximately day 7-14 . Patients also receive G-CSF SQ IV blood count recover . Cohorts 3-6 patient receive escalate radiological dos 90Y-MN-14 maximum tolerate dose ( MTD ) determine . The MTD define either dose 1 6 patient experience dose limit toxicity threshold radiation dose lung , kidney , liver . Patients follow weekly first month , monthly 3 month , every 6 month 5 year . PROJECTED ACCRUAL : Approximately 30 patient accrue stratum study within 3 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven medullary thyroid carcinoma Unresectable localregional disease OR Distant metastases Autologous peripheral blood stem cell ( PBSC ) bone marrow available Diffuse bone/marrow involvement allow : Autologous bone marrow PBSC great 5 % tumor involvement available Radiation dose marrow great 3000 cGy 6 patient treat safely dose level At least 1 site confirm CT target pretherapy indium In 111 monoclonal antibody MN14 image PATIENT CHARACTERISTICS : Age : 16 80 Performance status : Karnofsky 60100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3000/mm3 Granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine le 1.5 time upper limit normal Cardiovascular : Ejection fraction least 50 % Other : No severe anorexia , nausea , vomit No concurrent significant medical complication would preclude compliance Not pregnant Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since biologic therapy Chemotherapy : At least 4 week since prior chemotherapy recover No great 240 mg/m2 doxorubicin total combination therapy doxorubicin great 550 mg/m2 doxorubicin radioimmunotherapy alone No prior failure doxorubicin therapy combination therapy radioimmunotherapy alone Endocrine therapy : Prior synthroid ( T4 ) allow Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy index lesion recover No prior radiotherapy great 35 % red marrow Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>thyroid gland medullary carcinoma</keyword>
</DOC>